New treatments in #psoriaticarthritis Deucravacitinib TYK2 inhibitor selectively mediates cytokine signaling, specific inflammatory pathways (eg, IL-23, IL-12, and Type I interferons) concomitant with clinical symptom improvement @RheumNow #ACR21 Abst#0490 https://t.co/7JZGa5R4eC
Links:
Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, …
https://bit.ly/3o18LLq
06-11-2021
